

Indices	Value	Pts	Chg (%)
SENSEX	33588.08	26.53	0.08
NIFTY	10348.75	6.45	0.06
SGX NIFTY*	10373.00	2.00	0.02
DOW Jones	23526.18	NT	NT
S&P 500	2597.08	NT	NT
Nasdaq	6867.36	NT	NT
FTSE	7417.24	(1.78)	(0.02)
CAC	5379.54	26.78	0.50
DAX	13008.55	(6.49)	(0.05)
Shanghai Composite*	3332.27	(19.65)	(0.59)
Nikkei*	22516.47	(6.68)	(0.03)
Hang Seng*	29772.20	64.26	0.22

*As at 8.30 am

Most Active Call & Put Symbol	Strike Price	OI	Chg (%)
NIFTY	10400 CE	5043900	(3.69)
NIFTY	10300 PE	6025500	10.82

Commodity	Value	Pts	Chg (%)
NYMEX Crude (USD)	58.45	0.43	0.74
Brent Crude (USD)	63.36	(0.19)	(0.30)
Gold (INR)	29439	(91.00)	(0.31)
Silver (INR)	39392	(177.00)	(0.45)
Copper (INR)	449	0.60	0.13
Zinc (INR)	211	(0.35)	(0.17)
Cotton (INR)	18520	10.00	0.05

Currency	Value	Pts	Chg (%)
USD/Rupee	64.67	0.09	0.14
Euro/Rupee	76.60	0.10	0.13
Pound/Rupee	85.94	0.04	0.05
Euro /USD	1.18	(0.00)	(0.03)
Dollar Index	93.20	(0.02)	(0.02)

Volatility	Value	Pts	Chg (%)
CBOE VIX	9.88	0.15	1.54
India VIX	13.86	(0.18)	(1.28)

Interest Rates	Value	Bps change
India 10-Yr Yield	7.01%	6
US 10-Yr Yield	2.34%	2

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	4422.42	29651.46	1134036.55
Advance (Nos)	1415(50%)	920(50%)	NA
Declines (Nos)	1284(45%)	801(45%)	NA
Unchanged	156(5%)	72(5%)	NA

Market Summary

The market ended on positive note on Thursday. The market breadth was positive 1 gainer for every 1 loser on BSE. 1415 shares advanced whereas 1284 shares declined and 156 shares were unchanged on BSE.

BSE Sensex gained 27 points or (0.1%) to close at 33588. Nifty 50 was up 6 point or (0.1%) to settle at 10349. BSE Mid-Cap index gained 51 points or (0.3%) to settle at 16836. BSE Small-Cap index advanced 90 points or (0.5%) to settle at 17944.

Top gainer in BSE Sensex were BHEL (4.6%), Infosys (2.6%) Sun Pharma (1.8%), Reliance (1.6%) and Axis Bank (0.8%) whereas top loser in BSE were Dr Reddys Labs (2.1%), Adani Ports (1.7%), Bajaj Auto (1.5%), Asian Paints (1.1%) and NTPC (0.9%).

US markets were closed yesterday.

European markets closed mixed, FTSE was down 2 points (0.0%) to close at 7417, CAC advanced 27 points (0.5%) to close at 5380 and DAX declined 6 points (0.1%) to close at 13009.

Macro News

- Government has given approval to India's membership for European Bank for Reconstruction and Development (EBRD). This move will improve investment opportunities of the country as well as the competitive strength of the Indian firms, and provide an enhanced access to international markets in terms of business opportunities, procurement activities, consultancy assignments etc. Besides, it is expected to increase the scope of cooperation between India and EBRD through co-financing opportunities in manufacturing, services, IT, and Energy. Membership of EBRD will also drive the growth of country's export. India will have to make minimum initial investment of ~1 mn euros for the membership and country will get the minimum 100 shares in the bank.

- Government constituted a task force for redrafting the 50-year-old income tax law in sync with the economic needs of the country. The panel has been tasked to draft a direct tax legislation keeping in view the tax system prevalent in various countries, the international best practices and economic needs of the country. The task force will submit its report to the government within six months

- Power generating companies will be allowed to pass on the cost of retrofitting coal based-power plant for meeting emission norms. The cost of retrofitting a power plant ranges from Rs 1-2 crore per megawatt while for new coal-fired plant the cost is pegged at Rs 5 crore per MW.

Institutional Activity	23-Nov	Cash Nov'2017
FIIs (INR Crs)		
Buy	4396	98263
Sell	4323	118856
Net	73	(20593)
DII (INR Crs)		
Buy	3101	68110
Sell	2879	60613
Net	222	7498

FII Derivative Statistics (NSE)				
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)	Chg (%)
INDEX FUTURES	1602.73	1458.93	334752	0.11
INDEX OPTIONS	67458.27	67963.37	1205506	(1.87)
STOCK FUTURES	7438.90	7338.24	1018524	(1.43)
STOCK OPTIONS	6647.50	6626.56	132383	0.59
Total	83147.39	83387.09		

Gainers & Losers	Price	Chg (%)
Gainers (INR)		
BHEL	92.85	4.62
Infosys	991.40	2.60
Sun Pharma	544.75	1.78
Reliance	945.15	1.60
Axis Bank	544.25	0.78
Losers (INR)		
Dr Reddys Labs	2311.65	(2.10)
Adani Ports	407.20	(1.71)
Bajaj Auto	3261.85	(1.52)
Asian Paints	1161.25	(1.12)
NTPC	180.00	(0.94)

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	17943.86	90.38	0.51
S&P BSE Mid-Cap	16836.18	50.77	0.30
S&P BSE Auto	25232.91	(57.70)	(0.23)
S&P BSE BANKEX	29190.15	0.77	0.00
S&P BSE Capital Goods	18415.76	81.91	0.45
S&P BSE FMCG	10313.81	8.56	0.08
S&P BSE Healthcare	13976.28	31.82	0.23
S&P BSE IT	10844.38	139.62	1.30
S&P BSE Metals	14314.29	(49.53)	(0.34)
S&P Oil & Gas	16010.51	56.96	0.36

Key News

CG Power bags order worth Rs 111 crore from Indian Railways

CG Power & Industrial Solutions has bagged an order of Rs 111 crore from Indian Railways for Drive Propulsion System of Electric Loco at Chittaranjan Locomotive Works. CG's Drive Propulsion System comprises of IGBT based Traction converter, Auxiliary converter, TCN based Vehicle control unit and Driver Display Unit which helps to run trains efficiently at a higher speed with reduced energy consumption. The order is significant to Indian Railways capacity enhancement plans and meets the demand for electric loco products with an emphasis on propulsion system. This opens up huge opportunities for CG especially in electric locomotives.

Welspun Corp bags order for supply of 392K MTs pipes

Welspun Corp has been awarded a contract from a customer in MENA Region for supply of 392 K MTs pipes for a water project in MENA Region. With the addition of this order, the company has crossed coveted 1 million MT mark and has current order book of 1,082 K MTs worth Rs 6300 crore. This new pipe contract exhibit the continued confidence of its clients in the company. Welspun Corp is currently in four businesses viz Line Pipes, Energy, Infrastructure & Steel and enjoys a global leadership position in the first two businesses. It may be recalled that Welspun Corp is already in advanced stages of demerging the parts of its business other than Line Pipes into Welspun Enterprises through a court process.

Zydus Cadila gets tentative approval for Tadalafil Tablets

Zydus Cadila has received the tentative approval from USFDA to market Tadalafil Tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. The drug is indicated for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 170 approvals and has so far filed over 310 ANDAs.

International Data

Country	Data	Forecast	Previous
US	Flash Manufacturing PMI	55.1	54.6

Sharad Avasthi

Head - Equity Research

sharad.avasthi@spagroupindia.com

Tel.: +91-022-42895600

Ext.206

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economicstimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
• Managing/co-managing public offering of securities	
• Investment banking/merchant banking/brokerage services	No
• products or services other than those above	
• in connection with research report	
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company:	No

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

For More Information Visit Us At : www.spasecurities.com

SPA CAPITAL SERVICES LIMITED

Investment Advisory services,
AMFI Reg. No. ARN-0007

SPA Capital Advisors Limited

SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825

SPA COMTRADE PRIVATE LIMITED

SPA INSURANCE BROKING SERVICES LTD.

Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03

SPA Securities Ltd

NSE Cash
NSE Future & Option
NSE Currency Derivatives
BSE Cash
BSE Currency Derivatives
MCX-SX Cash
MCX-SX Future & Option
MCX-SX Currency Derivatives
Mutual Fund
CDSL DP
NSDL DP
SEBI Research Analyst

SEBI Reg. Nos.

INB231178238
INF231173238
INE231178238
INB011178234
INE011178234
INB261178231
INF261178231
INE261178238
ARN 77388
IN-DP-CDSL-485-2008
IN-DP-NSDL-316-2009
INH100002615